Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Google Secures Pentagon AI Deal for Classified Projects 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
NEWTON, Mass., Feb. 03, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming Leerink Partners 5th Annual Global Healthcare Conference in New York on Wednesday, February 10, 2016 at 11:30 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm’s SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of inflammation, autoimmune disease, neurological disorders, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
